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SUMMARY
Mice carrying a hypomorphic point mutation in the Ptpn6 gene (Ptpn6 spin mice) develop an inflammatory skin disease that resembles neutrophilic dermatosis in humans. Here, we demonstrated that interleukin1a (IL-1a) signaling through IL-1R and MyD88 in both stromal and immune cells drive inflammation in Ptpn6 spin mice. We further identified SYK as a critical kinase that phosphorylates MyD88, promoted MyD88-dependent signaling and mediates dermatosis in Ptpn6 spin mice. Our studies further demonstrated that SHP1 encoded by Ptpn6 binds and suppresses SYK activation to inhibit MyD88 phosphorylation. Downstream of SHP1 and SYKdependent counterregulation of MyD88 tyrosine phosphorylation, we have demonstrated that the scaffolding function of receptor interacting protein kinase 1 (RIPK1) and tumor growth factor-b activated kinase 1 (TAK1)-mediating signaling were required to spur inflammatory disease. Overall, these studies identify SHP1 and SYK crosstalk as a critical regulator of MyD88 post-translational modifications and IL-1-driven inflammation.
INTRODUCTION
Mutations in the PTPN6 gene that encodes for the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-1 (SHP1) have been linked with autoinflammatory and autoimmune diseases in humans (Cao and Hegele, 2002; Christophi et al., 2008) . Several mouse models with mutations in the Ptpn6 gene have been described and present with very severe autoinflammatory syndromes as described in the humans (Croker et al., 2008; Green and Shultz, 1975; Shultz et al., 1984; Shultz et al., 1993; Tsui et al., 1993) . Motheaten mice (a recessive mutation of Ptpn6 gene resulting in motheaten phenotype, Ptpn6 me/me ), first described in 1975, have deletion of a cytosine (C) nucleotide in position 228 of the Ptpn6 gene resulting in complete deletion of full normal SHP1 (Green and Shultz, 1975; Wishcamper et al., 2001) , although other splice variants of SHP1 have been reported to be functional in these mice (Martin et al., 1999) . Ptpn6 me/me mice exhibit severe dysfunction of the immune system, develop inflammatory lesions with neutrophil infiltration, and die around 3-4 weeks of age (Green and Shultz, 1975; Wishcamper et al., 2001 ). Motheaten-viable mice (a hypomorphic allele due to a T-to-A transversion at a splice consensus site, Ptpn6 me-v/me-v mice) also develop myeloproliferative disease and die around 9-10 weeks of age (Shultz et al., 1984; Tsui et al., 1993) . While these mouse models have demonstrated critical roles for SHP1 in various immune cells, the premature death of these mice has hindered complete characterization of SHP1 in the context of inflammatory diseases. Recent characterization of a hypomorphic Ptpn6 mutant mouse with homozygous Tyr208Asn amino acid mutation (exhibits spontaneous inflammation, or spin, and referred to as Ptpn6 spin mice here) has uncovered a critical role of SHP1 in regulating inflammatory disorders. Ptpn6 spin mice display a similar myeloproliferative disorder and footpad inflammation as the motheaten mice; however, unlike the motheaten mice, Ptpn6 spin mice survive into adulthood (Croker et al., 2008) . Moreover Ptpn6 spin mice develop persistent footpad swelling and suppurative inflammation that is very similar to neutrophilic dermatosis in humans (Croker et al., 2008; Nesterovitch et al., 2011) . While the essential roles of interleukin (IL)-1 in promoting these autoinflammatory diseases are well established, it is only recently that the specific roles for IL-1a and IL-1b have been recognized (Lukens et al., 2014; Lukens et al., 2013) . Using Ptpn6 spin mice as a model of inflammatory disease, we previously showed that IL-1a, but not IL-1b or the caspase-1-associated inflammasome is a central cytokine that promotes neutrophilic footpad inflammation (Lukens et al., 2013) . Mechanistically, RIPK1 has been shown to regulate IL-1a expression independently of RIPK3, suggesting a role for RIPK1 and IL-1a signaling axis in driving footpad inflammation (Lukens et al., 2013) . Several studies including ours have demonstrated that hematopoietic or neutrophil specific deletion of Ptpn6 is sufficient to promote neutrophilic footpad inflammation (Abram et al., 2013; Lukens et al., 2013) . However, the precise molecular events downstream of IL-1a as well as how RIPK1 instigates footpad inflammation provoked by the Ptpn6 spin (or SHP1-deficient) myeloid cells are unknown. More importantly, the regulatory functions of SHP1 remain completely uncharacterized. Thus, understanding the molecular mechanisms of RIPK1 and IL-1a signaling axis, and SHP1 functions that regulates inflammation is required. Here, we have characterized the molecular underpinnings of RIPK1-dependent control of autoinflammatory disease and established the role for tumor necrosis factor (TNF) downstream of IL-1a that drive inflammatory disease. We have shown that the RIPK1 scaffolding function, but not its kinase activity or necroptosis promoted disease in Ptpn6 spin mice. Mechanistically, we established that TAK1 in myeloid cells were critical to provoke this neutrophilic disorder suggesting a role for RIPK1 and TAK1 signaling axis. We further report that spleen tyrosine kinase (SYK) is a critical kinase that is centrally required for the instigation of inflammatory disease in Ptpn6 spin mice. We also characterized and elucidated SHP1-mediated regulation of SYK activation in controlling MyD88 phosphorylation as a prominent mechanism that controls autoinflammation and skin disease in Ptpn6 spin mice.
RESULTS

Ptpn6
spin Mutation in the Non-Hematopoietic
Compartment Is Dispensable for Inflammatory Disease IL-1 receptor signaling and MyD88 are centrally required for provoking inflammation and inflammatory skin disease in Ptpn6 spin mice (Croker et al., 2008; Lukens et al., 2013 1A and 1B and Table S1 ). In addition, the monocyte and Disease curve in (A) and (D) was analyzed by Log-rank (Mantel-Cox) test. All data are presented as mean ± SEM. Each point represents single mouse and MannWhitney test was used to determine significance between the two groups analyzed (C). ***p < 0.001 ****p < 0.0001. Please see also Table S1 .
neutrophil populations noted in Ptpn6 spin mice (Lukens et al., 2013) were also elevated in Ptpn6 fl/fl 3 Lyz2 cre+ mice relative to those of their littermate controls ( Figure 1C ). These studies confirm that SHP1 deficiency in myeloid cells is sufficient to drive this autoinflammatory disease, which is in line with previously published results (Abram et al., 2013; Lukens et al., 2013 Figure S1 and S2.
tion in Ptpn6 spin mice is mainly confined to the hind footpads, we proposed that IL-1a is released by footpad radioresistant cells during normal wound healing responses. Indeed, wound-healing experiments have shown that IL-1a amounts are highly elevated following microabrasion injury (Lukens et al., 2013) . To this end, we generated specific Ptpn6 spin chimeras to examine the role of stromal IL-1a in the progression of footpad inflammation (Figure 2A ). Ptpn6 spin >> Il1a À/À chimera mice were completely protected from disease progression (Figure 2A) . In contrast, bone marrow cells from protected Ptpn6 spin 3 Il1a À/À mice, when transferred to WT recipients promoted disease, which further underscores the requirement of IL-1a in the radioresistant but not the hematopoietic compartment (Figure 2B ). These findings reveal crosstalk between radioresistant and hematopoietic compartments whereby SHP1-deficient myeloid cells overreact to the release of IL-1a by radioresistant cells during injury, which ultimately results in a self-perpetuating inflammatory skin disease. IL-1R-mediated signaling was required for disease development ( Figure S1A In addition to the normal damage and repair process (that is potentially driven by IL-1a; Chen et al., 2007; Cohen et al., 2010; Rider et al., 2011) , the footpads are also in constant contact with commensal microorganisms, which might contribute to the modulation of IL-1a expression in stromal cells. Furthermore, several studies have shown that skin-specific commensal microbiota are involved in immunity (Naik et al., 2015; Naik et al., 2012) . Thus, we speculated that microbiota could influence disease progression in Ptpn6 spin mice. Indeed, our studies analyzing 16S ribosomal RNA (rRNA) metagenomic sequencing of intestinal microbiome showed that the microbial landscape was altered in Ptpn6 spin mice ( Figures S2A and S2B ). To investigate the potential role of microbiota in promoting Ptpn6 spinmediated inflammatory disease, we administered pre-diseased Ptpn6 spin mice full spectrum antibiotics (ABX). Whereas all Ptpn6 spin mice on untreated water developed footpad inflammation before day 100, Ptpn6 spin mice on ABX water were protected and showed no disease ( Figure S2C ). Taken together, it could be postulated that microbiota primes IL-1a expression in radioresistant compartment, which when released can promote inflammatory disease in Ptpn6 spin mice.
IL-1a-Induced TNF Contributes to Inflammatory Disease in Ptpn6 spin Mice
Myeloid cells, specifically neutrophils, are hyperactivated in Ptpn6 spin mice and produce exacerbated amounts of pro-inflammatory cytokines such as G-CSF, KC, and IL-6 (Lukens et al., 2013) . Furthermore, we previously showed that microabrasion injury promotes IL-1a secretion and disease induction in Ptpn6 spin mice (Lukens et al., 2013) . We used this experimental setup to determine the apical cytokines instigating the inflammatory cascade. WT footpads that were microabrated produced appreciable amounts of TNF, IL-1a, G-CSF, and KC ( Figures  3A-3D ). In line with our hypothesis that IL-1a is the apical cytokine, production of TNF as well as G-CSF and KC following microabrasion injury was dependent on IL-1a ( Figures 3A, 3C , and 3D). However, the production of IL-1a as well as G-CSF and KC in microabrated footpads of Tnf À/À mice was similar to those of WT mice . These data altogether demonstrate IL-1a as the apical cytokine that instigates the inflammatory cascade in the footpads. To further examine whether TNF plays a pathogenic role in Ptpn6 spin -mediated skin disease, we generated Ptpn6
and
Ptpn6 spin 3 Tnf À/À mice. As expected, Ptpn6 spin 3 Il1a À/À ,
Ptpn6
spin 3 Il1r1 À/À , and Ptpn6 spin 3 Myd88 À/À mice generated in our facility showed complete protection and were disease free until the end of the experiment, whereas 100% of Ptpn6 spin mice developed footpad inflammation by day 90 (Figure 3E and Figure S1) . Ptpn6 spin 3 Tnf À/À mice demonstrated significantly delayed disease progression than did Ptpn6 spin mice, and approximately 50% of the Ptpn6 spin 3 Tnf À/À mice remained completely protected ( Figure 3E ). TNF engages adaptor molecule TRADD to induce its downstream signaling events. In line with the disease incidence in Ptpn6
mice showed significantly delayed disease development compared to Ptpn6 spin mice ( Figure 3F ). Further, approximately 50% of the Ptpn6 spin 3 Tradd À/À mice also remained completely disease free ( Figure 3F ). Taken together, these results are consistent with the hypothesis that IL-1a acts as an apical cytokine that promotes subsequent production of TNF and other proinflammatory cytokines (G-CSF, KC) that ultimately recruit myeloid cells to drive the autoinflammatory skin disease in Ptpn6 spin mice ( Figures 3A-3F ). It is important to note that while the protection with IL-1a-deficiency was complete, deletion of the TNF-signaling pathway components only provided partial protection. Given that G-CSF has also been shown to be involved in the progression of disease (Croker et al., 2011) , it is possible that TNF, G-CSF, and other cytokines and chemokines have redundant roles downstream of IL-1a. Figure S3A ). TRIF is an important adaptor relaying Toll-like receptor (TLR)3 and TLR4 signaling, which can induce IL-1a production. However, we found Ptpn6 spin 3 Trif À/À mice developed disease comparable to that of Ptpn6 spin mice, indicating that TLR3 signaling and the MyD88-independent TLR4 signaling axis were dispensable for disease progression ( Figure S3B ). We next generated Ptpn6 spin 3 Tlr2
Inflammation in
investigate the putative roles of TLR2 and TLR4 in Ptpn6 spin -associated skin inflammation. Neither single nor combined deletion of TLR2 and TLR4 rescued disease progression in Ptpn6 spin mice ( Figure 3G ). Moreover, Ptpn6 spin mice deficient in TLR3, TLR7, and TLR9 also developed disease at a similar rate when compared to Ptpn6 spin mice ( Figure 3H ). Given these results, we hypothesized that other NF-kB-and ERK-activating mechanisms might contribute to Ptpn6 spininduced inflammatory disease (Lukens et al., 2013) . NOD1-and NOD2-induced NF-kB and ERK signaling are mediated by RIPK2 (Inohara et al., 2000; Ogura et al., 2001 ), a protein kinase that is closely related to RIPK1. To determine whether NOD1 and/or NOD2 signaling contributed to disease progression in Ptpn6 spin mice, we generated Ptpn6 spin mice that were deficient in NOD2 or RIPK2. However, both Ptpn6 spin 3 Nod2 À/À and
Because type I interferon (IFN) signatures are a hallmark of autoimmune diseases and play a critical role in driving disease pathogenesis (Banchereau and Pascual, 2006) Figure 3I ).
STING (encoded by Tmem173 gene) is a central adaptor for DNA sensors, and autoimmune disease associated with defects in DNA processing can be rescued by STING deficiency (Cai et al., 2014) . STING deficiency, however, did not block the progression of footpad inflammation in Ptpn6 spin mice ( Figure 3J ). Disease observed in Ptpn6 spin mice is independent of inflammasome, caspase-1, and pyroptotic cell death (Lukens et al., 2013) . However, we recently showed that caspase-1 and caspase-8 play redundant roles in Pstpip2 cmo -mediated autoimmune osteomyelitis (Gurung et al., 2016; Lukens et al., 2014) . Contrastingly, caspase-1 and caspase-8 deficiency together did not provide protection from Ptpn6 spin -mediated disease ( Figure S3D ).
Altogether, these results demonstrate that TLR2, TLR3, TLR4, TLR7, TLR9, TRIF, NOD1, NOD2, RIPK2, type I IFN, STING, integrin-signaling axes, caspase-1, and caspase-8 are all dispensable for Ptpn6 spin -mediated footpad inflammation.
RIPK1 Scaffolding Function Provokes Disease in
Increased IL-1a expression following microabrasion injury of footpads can be rescued by Nec1 treatment, a pharmacological , and Ptpn6 spin 3 Ifnar2 À/À mice were observed for disease progression.
(J) Ptpn6 spin and Ptpn6 spin 3 Tmem173 gt/gt mice were observed for disease progression.
Disease curves of Ptpn6 spin mice and the experimental Ptpn6 spin crosses were analyzed by Log-rank (Mantel-Cox) test. Mann-Whitney testing was used to determine the significance between the two groups analyzed (A-D). *p < 0.05, **p < 0.01, ns = not significant. Please see also Figure S3 .
inhibitor of RIPK1 (Lukens et al., 2013) . However, studying the genetic contribution of RIPK1 in Ptpn6 spin -associated disease had been hampered by perinatal lethality associated with RIPK1-deficient mice (Kelliher et al., 1998) . Recent reports have shown that perinatal death of Ripk1 À/À mice can be rescued by deleting both RIPK3 and caspase-8 (i.e., Casp8 À/À 3 Ripk3 À/À 3 Ripk1 À/À mice are normal at birth and survive perinatal death) (Dillon et al., 2014; Kaiser et al., 2014; Rickard et al., 2014) . To investigate whether germline deletion of RIPK1 rescues disease in Ptpn6 spin mice, we generated Ptpn6 spin 3 Figure 4A ). Although all Figure S3E ). In agreement with results from recently reported fetal liver chimera studies (Lukens et al., 2013) , our results confirmed a critical role for RIPK1 in controlling Ptpn6 spin -mediated skin disease. RIPK1 has several important functions that can act independently to affect cellular functions (Weinlich and Green, 2014) . RIPK1 can phosphorylate target proteins, promote necroptosis (in combination with RIPK3), or act as a scaffold protein. K45A and D148N mutations in RIPK1 eliminate its kinase activity Polykratis et al., 2014) . To determine whether RIPK1 kinase activity is required for autoinflammation in Ptpn6 spin mice, we generated Ptpn6 spin 3 Ripk1 K45A mice (Figure 4C ). Ptpn6 spin 3 Ripk1 K45A mice developed disease and histological lesions similar to that of Ptpn6 spin mice ( Figures 4C and  4D ). Although we previously ruled out a role for RIPK3 in skin inflammation ( Figure 4A ) (Lukens et al., 2013) , we hypothesized that RIPK1 might coordinate necroptosis by activating mixed lineage kinase domain-like (MLKL) in a RIPK3-independent fashion. MLKL is an obligate pseudokinase that promotes necroptosis by facilitating pore formation in the plasma membrane (Dondelinger et al., 2014 While we have shown specific roles for IL-1a, TNF, and RIPK1-TAK1 signaling axis in promoting skin inflammation in Ptpn6 spin mice (Figures 1, 2, 3 , and 4), the molecular targets of SHP1 and how SHP1 regulates inflammation are not known. SHP1 is a tyrosine phosphatase that dephosphorylates target proteins to exert its function (Zhang et al., 2000) . Previous studies have shown that SHP1 regulates cell survival, proliferation, migration, and inflammation through the control of major signaling pathways that include AKT, JAK-STAT, MAPK, and NF-kB (Chong and Maiese, 2007 ). In line with previous studies (Croker et al., 2008) , our data presented here demonstrated a critical role for MyD88 in promoting inflammation in Ptpn6 spin mice ( Figure S1B ). To determine whether MyD88 is required in the hematopoietic or radioresistant compartment, we generated 5D ). Altogether, these studies show that MyD88 signaling is required in both hematopoietic and radioresistant compartments to promote inflammatory skin disease in Ptpn6 spin mice.
SHP1 Interacts with MyD88 and Regulates Phosphorylation of MyD88 Tyrosine Residues
Given that the Ptpn6 spin mutation in hematopoietic cells is critical for disease induction (Figure 1 ), we hypothesized that SHP1-dependent regulation of tyrosine phosphorylation might likely be affected in myeloid cells. To address to what extent global tyrosine phosphorylation were altered in Ptpn6 spin myeloid cells, we analyzed cell lysates of IL-1a-stimulated WT and Ptpn6 spin myeloid cells by immunoblotting using the pTyr antibody 4G10. Although we did not detect a global increase in tyrosine phosphorylation in Ptpn6 spin cell lysates, selected proteins were found hyperphosphorylated following IL-1a stimulation when compared to WT cell lysates, consistent with specificity to SHP1 function ( Figure 5E ). Considering that MyD88 is critical for regulating NF-kB and MAPK signaling pathways downstream of IL-1R, we co-immunoprecipitated tyrosine phosphorylated proteins with pTyr (4G10) antibodies and probed the co-immunoprecipitated lysates for MyD88. IL-1a treatment of WT myeloid cells resulted in a decrease in MyD88 tyrosine phosphorylation. In contrast, MyD88 remained stably phosphorylated following IL-1a stimulation of SHP1-deficient cells ( Figure 5F , left panel). Similar to primary cells, MyD88 expressed in HEK293 C6 cells (IL-1R1 stably expressed) was also tyrosine phosphorylated following IL-1a stimulation ( Figure 5F , right panel). These findings show that (1) MyD88 is phosphorylated on tyrosine residues and (2) the SPIN mutation, which attenuates SHP1 function, leads to sustained elevated tyrosine phosphorylation of MyD88 during IL-1a stimulation.
SHP1 contains Src homology 2 (SH2) domain that it utilizes to bind to phosphorylated tyrosine residues on target proteins (Chong and Maiese, 2007) . In fact, the SPIN mutation, Y208N, alters a residue in the sequence linking the two SH2 domains. We examined whether SHP1 interacted with MyD88 by overexpressing both SHP1 and MyD88 in HEK293 C6 cells. Our results The disease curves for Ptpn6 spin mice and the experimental group were analyzed by Log-rank (Mantel-Cox) testing. ns = not significant. Please see also Figure S3 . demonstrated that, following IL-1a stimulation, SHP1 interacted with MyD88 ( Figure 5G, upper panel) . Furthermore, the substrate-trapping mutant form of SHP1 (SHP1 DA) and the functionally attenuated SHP1 from Ptpn6 spin mice (SHP1 Y208N) interacted with MyD88 similar to WT SHP1 ( Figure 5G) . Additionally, mutating a predicted MyD88 tyrosine residue at 116 to phenylalanine (this tyrosine residue is absent in alternatively spliced MyD88 [MyD88s], which act as a negative regulator of IL-1R signaling; Burns et al., 2003) did not prevent SHP1 interaction with MyD88 ( Figure 5G ). The interactions between SHP1 and MyD88 were specific because similarly overexpressed SHP2 did not interact with MyD88 ( Figure 5G, lower panel) . These data demonstrate a previously uncharacterized role for SHP1 in regulating MyD88 phosphorylation and suggest a potential role for this event in preventing autoinflammatory skin disease.
SYK Phosphorylates MyD88, and SHP1 Inhibits SYK Activation to Regulate MyD88 Phosphorylation
To further delineate the molecular mechanisms involved in tyrosine phosphorylation of MyD88, we investigated potential tyrosine kinases that could phosphorylate MyD88. Our study showed that SYK, but not breast tumor kinase (BRK) or Bruton's tyrosine kinase (BTK) was able to specifically phosphorylate MyD88 ( Figure 6A ). We next examined the tyrosine residues on MyD88 that were phosphorylated by SYK by co-transfecting WT or mutant MyD88 along with SYK in HEK293 cells. Our data suggest that tyrosine residues 180 and 278 are two potential sites on MyD88 phosphorylated by SYK ( Figure 6B and Figure S4A) . We also observed that mutating Y71 residue resulted in increased phosphorylation of MyD88. Phosphorylation of Y71 might act in a self-regulatory negative feedback loop to inhibit additional tyrosine phosphorylation of MyD88. One possible mechanism could be that Y71 phosphorylation recruits additional proteins to halt MyD88 phosphorylation. Whether increased MyD88 phosphorylation observed in Y71F mutants have any functional consequence is not clear and will need further investigation.
It can be posited that SHP1 could directly regulate MyD88 phosphorylation (through its phosphatase activity), or indirectly regulate MyD88 phosphorylation by regulating SYK activation (SYK phosphorylates MyD88; Figure 6A ). To test whether SHP1 directly regulates MyD88 phosphorylation, we performed an in vitro dephosphorylation assay where phosphorylated MyD88 was mixed with WT or Y208N mutant SHP1 ( Figure S4B ). Both WT and mutant SHP1 were unable to dephosphorylate MyD88, suggesting that SHP1 does not regulate MyD88 phosphorylation directly ( Figure S4B ). Expression of SYK and MyD88 in HEK293 C6 cells resulted in SYK-dependent MyD88 phosphorylation, which is dephosphorylated by WT SHP1, but to a lesser extent by Y208N or DA mutant SHP1 ( Figure 6C ). In these studies, WT SHP1 but not Y208N or DA mutant SHP1 reduced phosphorylation of SYK, suggesting a role for SHP1 in inhibiting SYK phosphorylation, which could be a possible mechanism for MyD88 dephosphorylation ( Figure 6C ). To determine whether SHP1 directly regulated SYK activation, we co-expressed SYK with either WT or mutant (Y208 or DA) SHP1. While WT SHP1 co-expression reduced SYK phosphorylation, Y208N or DA SHP1 was less efficient at dephosphorylating SYK (Figure 6D ). In line with our hypothesis that SYK regulates IL-1 induced MyD88 signaling, IL-1a-induced NF-kB and ERK activation were blunted in the SYK-deficient myeloid cells ( Figure S5 ). These data altogether uncover a previously uncharacterized signaling pathway in which SYK phosphorylates MyD88 and where SHP1 directly regulates SYK activation. Whether SYK is a global regulator of MyD88 signaling is not fully understood and will require further investigation. Figures 6E and 6F) . Thus, conditional deletion of SYK specifically in the myeloid cells is sufficient to provide protection from skin inflammation observed in the Ptpn6 spin mice.
SYK Deficiency in
DISCUSSION
Polymorphisms in the human PTPN6 gene are associated with a wide spectrum of autoinflammatory diseases (Cao and Hegele, 2002; Christophi et al., 2008) . Therefore, understanding the basic biology and molecular mechanisms of these inflammatory disorders is crucial for developing improved treatment options. Using Ptpn6 spin and myeloid-specific SHP1-deficient (Ptpn6 fl/fl 3 Lyz2 cre+ ) mouse models, we have discovered several critical checkpoints and complex crosstalk between myeloid and (E) Myeloid cells from WT and Ptpn6 spin mice were stimulated with 20 ng/ml IL-1a for 20 or 40 min. Cell lysates were collected at the end of the experiment and probed with pan-phosphotyrosine (pTyr) antibody (Clone 4G10). Two different exposures (short and long) of the tyrosine phosphorylation blots are shown. Actin and MyD88 are used as protein loading controls. (F) Cell lysates prepared as in ''E'' were immunoprecipitated by using pTyr antibody and probed for MyD88 to show tyrosine phosphorylation of MyD88 (left panel). Flag-tagged MyD88 was transfected in HEK293 C6 cells and probed for tyrosine phosphorylation by using pTyr antibody after MyD88 immunoprecipitation (right panel).
(G) HEK293 C6 cells were co-transfected with indicated MyD88 and SHP1 constructs containing indicated proteins and the interaction of SHP1 and MyD88 were determined following MyD88 pull-down by western blot (upper panel). HEK293 C6 cells were co-transfected with MyD88 and SHP2 and interaction of MyD88 and SHP2 were determined by western blot (lower panel). Disease curves in (A) and (C) were analyzed by Log-rank (Mantel-Cox) testing. All western blot data in (E-G) are representative of at least three independent experiments. p < 0.05 is considered statistically significant. radioresistant cells that are crucial in driving this inflammatory disease. We undertook a genetic approach to define the molecular mechanisms and signaling pathways that are regulated by SHP1 to modulate inflammation. We demonstrated a central role for IL-1a, IL-1R, MyD88, SYK, RIPK1, and TAK1 in promoting inflammatory disease in Ptpn6 spin mice (mice with reduced SHP1 phosphatase activity). Importantly, in addition to demonstrating a central role for these molecules in the IL-1R signaling pathway, we also excluded the role of several other signaling pathways. Our studies showed that disease in Ptpn6 spin mice is independent of IFNAR-signaling, STING (involved in DNA sensing pathway), ITGB3 (Integrin) and NOD2-RIPK2 signaling axis. These studies, although negative, are critical in reinforcing the specific role of IL-1a signaling axis in provoking inflammatory disease in Ptpn6 spin mice.
RIPK1-deficient mice suffer from perinatal death making it difficult to study the role of this molecule in Ptpn6 spin -mediated inflammatory disease (Kelliher et al., 1998) . To circumvent this perinatal lethality, Ptpn6 spin 3 Ripk1 À/À fetal liver chimeras were generated, which were protected from disease (Lukens et al., 2013) . Recent studies have shown that Ripk1 À/À cells undergo cell death, and thus it could be implied that the protection observed in Ptpn6 spin 3 Ripk1 À/À fetal liver chimeras could be due to the gradual loss of these RIPK1-deficient Ptpn6 spin cells.
Therefore to further ascertain the role of RIPK1 in this inflammatory skin disease, we took advantage of Casp8
Ripk1 À/À mice, which were crossed with Ptpn6 spin mice (Dillon et al., 2014; Kaiser et al., 2014; Rickard et al., 2014) . (Ajibade et al., 2012; Elefteriou and Yang, 2011; Lamothe et al., 2012) . MyD88 is a central adaptor molecule for TLRs and IL-1R, and induce activation of several critical signaling pathways. The importance of MyD88 in pathogen sensing has been well established in the field as demonstrated by the heightened susceptibility of Myd88 À/À mice to variety of infections. As demonstrated by our group and others, MyD88 plays an essential role in inflammatory disease in Ptpn6 spin mice (Croker et al., 2008) . Here, we further demonstrated that MyD88 was required in both hematopoietic and radioresistant compartments to provoke disease in Ptpn6 spin mice. The requirement of MyD88 in the Ptpn6 spin myeloid cells was so that they could respond to IL-1a cytokines that were released by the radioresistant cells. Why MyD88 is required in the radioresistant compartment is not clear; however, we can envision at least two scenarios that may potentially explain the requirement for MyD88 in the radioresistant compartment. One, IL-1R is required in the radioresistant compartment (i.e., Ptpn6 spin >> Il1r1 À/À mice are protected; Figure 2C ) and thus IL-1a released by the radioresistant cells might act in a positive feedback loop through IL-1R-MyD88 signaling in the radioresistant compartment to amplify cytokine response and to recruit the disease instigating Ptpn6 spin myeloid cells. Second, MyD88 could be required for microbiota-induced IL-1a expression. This second possibility is supported by our studies and a published study (Croker et al., 2008) , which both demonstrate that the microbiome is required for disease development in Ptpn6 spin mice. These hypotheses are supported by studies that show that Ptpn6 spin mice derived in germ-free facilities do not develop the inflammatory disease (Croker et al., 2008) .
Although the molecular mechanisms involved in the MyD88 signaling have been thoroughly explored; how posttranslational modifications of MyD88 affects its signaling activity has been severely understudied (Deguine and Barton, 2014) . Herein, we report that MyD88 is posttranslationally modified via its tyrosine residue phosphorylation. More importantly, we have also identified SYK as the kinase that phosphorylates MyD88. Additional studies are needed to study the functional consequence of these posttranslational modifications on MyD88 and how they impact the inflammatory disease in Ptpn6 spin mice.
In conclusion, we have shown that IL-1a is an apical cytokine that regulates production of TNF, G-CSF, and KC to drive inflammatory disease observed in Ptpn6 spin mice. We have demonstrated that RIPK1 scaffolding function and TAK1-mediated signaling in myeloid cells are central regulators of footpad inflammation in Ptpn6 spin mice. We further revealed that MyD88 play critical roles in both the hematopoietic and stromal compartments in Ptpn6 spin -mediated disease. We also demonstrated that SYK is a critical tyrosine kinase that promotes MyD88 phosphorylation and provokes disease in Ptpn6 spin mice. Our studies revealed that attenuation of SHP1 by a SPIN mutation is associated with elevated MyD88 phosphorylation during IL-1a signaling events. Finally, we showed that SHP1 controls SYK activation to regulate MyD88 phosphorylation. Our results have (C) Indicated constructs were transfected in 293 C6 cell. Before harvest, cells were stimulated with IL-1a (20 ng/ml) for 20 min. Cell lysates were immunoprecipitated with anti-HA resin, and probed for tyrosine phosphorylation (4G10) and total HA-MyD88 pull-down. Same lysates were also immunoprecipitated with anti-SHP1 antibody and probed for HA to assess the interaction between SHP1 (WT or mutants) and HA-MyD88. The expression of HA-MyD88, SYK, and SHP1, as well as pSYK (pY525/6) was probed, respectively, in whole cell lysate extracts.
(D) FLAG-tagged SYK and SHP1 (WT or mutants) were transfected alone or together, as indicated, in 293 C6 cell. Before harvest, cells were stimulated with IL-1a (20 ng/ml) for 20 min. Cell lysates were immunoprecipitated with anti-FLAG resin, and probed for SHP1 antibody to assess the interaction between FLAG-SYK and SHP1 (WT or mutants). Histopathology Formalin-preserved feet were processed and embedded in paraffin according to standard procedures. Sections (5-mm thick) were stained with hematoxylin and eosin (H&E), and images were acquired using light microscopy.
Microabrasion Injury Model
WT, Il1a
, and Tnf À/À mice were anesthetized in Isoflurane chambers, and the plantar surfaces of hind paws were irritated to induce physical trauma by gently rubbing with sterile sandpaper 10 times. Mice were euthanized 6 hr post microabrasion, and footpads were analyzed for protein expression of IL-1a, TNF, G-CSF, and KC by performing ELISAs.
ELISA
Cytokine ELISAs were performed according to the manufacturer's instructions (Milliplex).
Flow Cytometry Protocols and Antibodies
CD11b (M1/70), and Gr-1 (RB6-8C5) antibodies from eBioscience were used for flow cytometry. Flow cytometry data were acquired on an upgraded eight-color FACScan and analyzed by using FlowJo software (Tree Star).
Bone Marrow Chimeras
Bone marrow was flushed from the femurs and filtered through a 40 mm filter. A total of 3 3 10 6 À5 3 10 6 cells in 200 mL PBS were transferred into lethally irradiated (1,000 rad) mice via retroorbital sinus injection.
Plasmids, Site-Directed Mutagenesis, and Transfection
The following mammalian expression plasmids were purchased from Addgene: MyD88-FLAG (#13093), HA-MyD88 (#12287); SYK (#20646), BTK (#20432) and pJ3-SHP1 (#8572). Other plasmid used in this study: pcDNA3.1-HA-SHP2 and pLPC-BRK. Agilent's manufacturer protocol was followed to perform site-directed mutagenesis. The following primers were used: SHP1 D419A trapping mutation (Fwd: gtacctgagctggcccgCccatggggtcccc, Rev: ggggaccccatggGcgggccag ctcaggtac); SHP1 Y208N Spin mutation (Fwd: ggcgcctttgtcAacctgcggcag ccgtac; Rev: gtacggctgccgcaggtTgacaaaggcgcc); SHP2 D425A trapping mutation (Fwd: cggacctggccggCccacggcgtgcccagc; Rev: gctgggcacgccgtgg Gccggccaggtccg); MyD88 (mouse) Y116F mutation (Fwd: ggactgccagaaatTc ttaggtaagcagcag; Rev: ctgctgcttacctaagAatttctggcagtcc); MyD88 (human) Y71F mutation (Fwd: ggagatggactttgagtTcttggagatccggc; Rev: gccggatctcca agAactcaaagtccatctcc); MyD88 (human) Y129F mutation (Fwd: ggaggattgcca aaagtTtatcttgaagcagc; Rev: gctgcttcaagataAacttttggcaatcctcc); MyD88 (human) Y180F mutation (Fwd: cgatgccttcatctgctTttgccccagcgac; Rev: gtcgct ggggcaaAagcagatgaaggcatcg); MyD88 (human) Y200F mutation (Fwd: ggaa cagacaaactTtcgactgaagttgtg; Rev: cacaacttcagtcgaAagtttgtctgttcc); MyD88 (human) Y248F mutation (Fwd: ggttgtctctgatgattTcctgcagagcaagg; Rev: ccttgctctgcaggAaatcatcagagacaacc); MyD88 (human) Y278F mutation (Fwd: gatccccatcaagtTcaaggcaatgaag; Rev: cttcattgccttgAacttgatggggatc); and MyD88 (human) Y297F mutation (Fwd: cactgtctgcgactTcaccaacccctgcacc; Rev: ggtgcaggggttggtgAagtcgcagacagtg).
Mirus' manufacturer protocol was followed to perform transient transfection (Transit-2020, Mirus) . In brief, HEK293 or HEK293 IL-1R1 C6 cells (from Geroge Stark, Cleveland Clinic) were seeded in a 6-well plate one day before transfection. Plasmid (2 mg) and Mirus transfection reagent (5 mL) were added to each well's experiment. Whole-cell lysates were collected 24 hr after transfection.
Antibodies and Immunoprecipitation
The following antibodies were used in the analysis:
From Millipore: phosphor-Tyr(4G10), phosphor-Tyr342, and total BRK; from Cell Signaling: phospho-Tyr525/6 and total SYK, phospho-Tyr223, and total BTK, ERK1/2; from Abcam: MyD88; from Santa Cruz: SHP1; from Covance: HA; from Sigma: FLAG and b-actin.
Cell extracts were prepared in lysis buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 1% NP-40, and freshly added protease inhibitor cocktail from Roche) and analyzed by performing SDS-PAGE and immunoblotting.
Pre-cleared cell extracts were incubated with the indicated antibody for 4 hr on a rotator in a cold room and then incubated 1:1 with Protein A/G agarose beads (GE) for 1h for immunoprecipitation. Immunoprecipitates were washed in lysis buffer three times before electrophoresis.
Statistical Analysis
All results are presented as means ± SE. Disease curves were analyzed by performing Log-rank (Mantel-Cox) testing, and significant differences between two groups were determined by performing Mann-Whitney test. Differences were considered statistically significant when p < 0.05. *p < 0.05, **p < 0.01, ***p < 0.001.
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